Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56. Following the transaction, the insider owned 178,326 shares in the company, valued at approximately $4,973,512.14. The trade was a 44.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):
- On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
- On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.
- On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total value of $4,812,181.01.
Alamar Biosciences Stock Performance
Shares of Alamar Biosciences stock traded up $3.29 during midday trading on Wednesday, hitting $31.45. The company’s stock had a trading volume of 1,141,204 shares, compared to its average volume of 725,622. The company’s 50-day simple moving average is $30.86. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. Alamar Biosciences, Inc. has a 1-year low of $18.84 and a 1-year high of $39.61.
Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The business had revenue of $29.43 million for the quarter. On average, sell-side analysts anticipate that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Alamar Biosciences
Institutional investors have recently modified their holdings of the stock. State Street Corp purchased a new position in shares of Alamar Biosciences during the 2nd quarter valued at $3,930,000. Squarepoint Ops LLC acquired a new position in shares of Alamar Biosciences in the second quarter worth $283,000. Braidwell LP acquired a new position in shares of Alamar Biosciences in the second quarter worth $29,365,000. Finally, Wellington Management Group LLP acquired a new position in shares of Alamar Biosciences in the second quarter worth $12,407,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Weiss Ratings upgraded Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Stifel Nicolaus upped their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. increased their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.80.
View Our Latest Research Report on Alamar Biosciences
About Alamar Biosciences
Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.
Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.
See Also
- Five stocks we like better than Alamar Biosciences
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
